Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
24 oct. 2024 07h30 HE
|
Soligenix, Inc.
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
Nufactor® Receives URAC’s Full Certification as a Rare Disease Pharmacy Center of Excellence
17 sept. 2024 13h34 HE
|
FFF Enterprises.com
TEMECULA, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Nufactor, Inc., a specialty infusion company and subsidiary of FFF Enterprises, Inc., is delighted to announce that it has received full...
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
07 août 2024 19h30 HE
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a...
Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone
01 août 2024 09h00 HE
|
PRISM Mediawire
Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone
Avance Clinical Announces Senior Appointment to North American Operations
31 juil. 2024 02h45 HE
|
Avance Clinical
ADELAIDE, Australia and WAKE FOREST, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, an award-winning, mid-sized full-service global Contract Research Organization (CRO) for biotech...
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
15 juil. 2024 10h16 HE
|
PRISM MarketView
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
Jura Health Welcomed by Colorado Medicaid as an Approved Provider for Testing for Suspected Rare Diseases
20 juin 2024 11h55 HE
|
Innosphere Ventures
Denver, Colorado, June 20, 2024 (GLOBE NEWSWIRE) -- Jura Health, an Innosphere Ventures client company, committed to health equity for rare disease patients and their families, is pleased to...
Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
05 juin 2024 08h00 HE
|
PRISM MarketView
Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
TrialWire Patient Recruitment Platform that Reboots Stalled Clinical Trials announced as Multi-Award Finalist in the 2024 Citeline Awards
12 mai 2024 16h29 HE
|
TrialWire
The TrialWire™ Rapid Patient Recruitment Platform, the only pay-per-enrolled fixed-fee solution powered by AI and algorithms, has been select for 3 awards
Using AI to Improve Diagnosis of Rare Genetic Disorders
25 avr. 2024 09h19 HE
|
Baylor Genetics
Diagnosing rare Mendelian disorders is a labor-intensive task, even for experienced geneticists. Investigators at Baylor College of Medicine are trying to